超短程糖皮质激素联合托珠单抗治疗巨细胞动脉炎:TOPAZIO研究扩展期结果
TOPAZIO扩展期研究纳入17例活动性大血管型巨细胞动脉炎患者,在3次静脉甲泼尼龙冲击后接受52周托珠单抗单药治疗,停药后观察26周。第78周PET血管活动评分(PETVAS)较基线显著下降,但较第52周显著升高;停药后无复发生存率随时间下降,PETVAS早期变化可能预测后续复发。
要点
- 52周托珠单抗单药治疗后停药,第78周PETVAS较基线平均下降6.6(95%CI -9.5至-3.7)。
- 停药6个月后PETVAS较第52周平均升高4.6(95%CI 0.7至8.5)。
- 第78周无复发临床缓解比例为11/17(65%,95%CI 38-86)。
核心结论
- 一年托珠单抗单药治疗可有效维持大血管型巨细胞动脉炎的无药临床缓解。
- 托珠单抗停药后早期PETVAS变化可能预测后续复发。
研究设计与样本
- TOPAZIO研究扩展期为26周观察性随访,纳入17例活动性大血管型巨细胞动脉炎患者。
- 患者先前接受3次静脉甲泼尼龙冲击及每周皮下托珠单抗单药治疗52周,第52周无复发临床缓解者停药进入第二部分。
- 所有患者在第78周(26周观察期结束时)行PET/CT检查。
主要发现
- 第78周PETVAS较基线平均变化为-6.6(95%CI -9.5至-3.7)。
- 第78周PETVAS较第52周平均变化为4.6(95%CI 0.7至8.5)。
- 第78周无复发临床缓解比例为11/17(65%,95%CI 38-86)。
- 随访结束时(距托珠单抗停药中位时间148周)无复发临床缓解比例为8/17(47%,95%CI 23-72)。
- 年龄和性别校正后,PETVAS每增加1单位提示后续复发的HR为1.36(95%CI 0.92-2.00)。
关键数值与推荐
- 第78周PETVAS较基线平均变化-6.6(95%CI -9.5至-3.7)。
- 第78周PETVAS较第52周平均变化4.6(95%CI 0.7至8.5)。
- 第78周无复发临床缓解11/17(65%,95%CI 38-86)。
- 随访结束时无复发临床缓解8/17(47%,95%CI 23-72),距停药中位时间148周。
- PETVAS每增加1单位提示后续复发的年龄和性别校正HR为1.36(95%CI 0.92-2.00)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the maintenance of efficacy of one year of tocilizumab (TCZ) monotherapy after its discontinuation in large vessel-GCA (LV-GCA). METHODS: 17 patients with active LV-GCA were previously treated with 3 boluses of intravenous methylprednisone and weekly subcutaneous TCZ in monotherapy for 52 weeks. Patients in relapse-free clinical remission at week 52 discontinued TCZ and entered part two, which was a 26-week observational follow-up period. PET/CT was performed in all patients at the end of the 26-week observational period (week 78). End points were the variation in PET vascular activity score (PETVAS) at week 78 compared with baseline and with week 52, and the proportion of patients with relapse-free clinical remission at week 78 and at the end of the follow-up. RESULTS: Compared with baseline, a significant reduction in PETVAS was observed at week 78, mean (95% CI) change -6.6 (-9.5 to -3.7). However, compared with week 52, PETVAS significantly increase 6 months after TCZ discontinuation (week 78), mean (95% CI) change 4.6 (0.7-8.5). The proportion of patients with relapse-free clinical remission at weeks 78 and at the end of the follow-up (median time from TCZ discontinuation 148 weeks) was 11/17 (65%, 95% CI 38-86) and 8/17 (47%, 95% CI 23-72), respectively. Age and sex-adjusted HR (95% CI) for each unit increase of PETVAS indicating subsequent relapse was 1.36 (0.92-2.00). CONCLUSIONS: One year of TCZ monotherapy was effective in maintaining drug-free clinical remission in LV-GCA. Changes in PETVAS early after TCZ discontinuation may predict subsequent relapses. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT05394909.
引用
- Muratore F, Marvisi C, Cassone G, et al. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study. Rheumatology (Oxford). 2025. PMID: 39150490. doi:10.1093/rheumatology/keae400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。